scientifyRESEARCH
research funding database

RESEARCH FUNDING

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)

Share this post

Logo of scientifyRESEARCH and Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.
Logo of scientifyRESEARCH + logo of Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.

The Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional) funding from the National Institutes of Health (NIH) supports translational and clinical research to:

  1. advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact;
  2. enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and
  3. discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children.

The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities. Applications are open to researchers in the USA and worldwide. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Opportunity number: PAR-23-130

Letters of intent are due: September 5, 2024.

Applications are due: October 5, 2024.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for the
scientifyRESEARCH
monthly funding newsletter

unsubscribe at any time